Predictions
MacroGenics Inc.
Start price
Target price
Perf. (%)
€3.84
17.10.22
17.10.22
-
17.10.23
17.10.23
40.63%
18.05.23
18.05.23
Risky Investment
Canopy Growth Corp
Start price
Target price
Perf. (%)
€2.44
17.10.22
17.10.22
-
17.10.23
17.10.23
-7.41%
22.12.22
22.12.22
Risky Investment
Invitae Corp
Start price
Target price
Perf. (%)
€2.14
16.10.22
16.10.22
-
16.10.23
16.10.23
-3.57%
18.02.23
18.02.23
Risky Investment
Abeona Therapeutics Inc.
Start price
Target price
Perf. (%)
€4.54
15.10.22
15.10.22
€2.00
15.10.23
15.10.23
-0.88%
29.10.22
29.10.22
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
First Wave BioPharma Inc.
Start price
Target price
Perf. (%)
€8.22
15.10.22
15.10.22
€0.000
15.10.23
15.10.23
2.13%
29.10.22
29.10.22
Low dividend yield expected
Bad rating
ROE lower than 10% per year
Sustainability is little important
Avenue Therapeutics Inc.
Start price
Target price
Perf. (%)
€3.63
14.10.22
14.10.22
€5.00
14.10.23
14.10.23
-84.59%
15.10.23
15.10.23
Could be worthwhile Investment >10% per year
B.R.A.I.N. Biotechnology Research and Information Network AG
Start price
Target price
Perf. (%)
€4.98
13.10.22
13.10.22
-
13.10.23
13.10.23
-18.27%
14.10.23
14.10.23
Canopy Growth Corp
Start price
Target price
Perf. (%)
€2.55
13.10.22
13.10.22
€2.30
13.10.23
13.10.23
42.55%
19.11.22
19.11.22
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
Risky balance sheet
Novavax Inc.
Start price
Target price
Perf. (%)
€21.36
13.10.22
13.10.22
€20.00
13.10.23
13.10.23
-48.44%
11.01.23
11.01.23
Very low/no dividend yield expected
very negative Cash Flow expected
ROE lower than 10% per year
high free float
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€67.38
13.10.22
13.10.22
€46.00
13.10.23
13.10.23
9.44%
14.10.23
14.10.23
Top 10 in its market
Good rating
Medium risks for its business
Bad culture
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€66.92
13.10.22
13.10.22
-
-
13.10.22
13.10.22
Top 10 in its market
Good rating
Medium risks for its business
Bad culture
Pulmatrix Inc.
Start price
Target price
Perf. (%)
€3.77
10.10.22
10.10.22
€6.00
31.12.24
31.12.24
-30.11%
05.05.23
05.05.23
Could be very worthwhile Investment >20% year
Motus GI Holdings Inc.
Start price
Target price
Perf. (%)
€1.97
10.10.22
10.10.22
€0.000
10.10.23
10.10.23
-6.09%
16.10.22
16.10.22
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Decining EBIT margin than peer group
Avenue Therapeutics Inc.
Start price
Target price
Perf. (%)
€2.86
08.10.22
08.10.22
€5.00
08.10.23
08.10.23
9.28%
16.10.22
16.10.22
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Cellectis SA ADR
Start price
Target price
Perf. (%)
€2.32
07.10.22
07.10.22
€5.00
07.10.23
07.10.23
-43.97%
08.10.23
08.10.23
Could be worthwhile Investment >10% per year
Avenue Therapeutics Inc.
Start price
Target price
Perf. (%)
€6.75
06.10.22
06.10.22
€0.000
06.10.23
06.10.23
-61.11%
24.10.22
24.10.22
Probably not worthwhile Investment
Revenue decline > 20% expected
EBIT decline > 20% expected
Decining EBIT margin than peer group
Eurobio scientific
Start price
Target price
Perf. (%)
€17.24
05.10.22
05.10.22
€18.00
05.10.23
05.10.23
-24.25%
06.10.23
06.10.23
Could be worthwhile Investment >10% per year
Euromedis Groupe
Start price
Target price
Perf. (%)
€4.10
04.10.22
04.10.22
-
04.10.23
04.10.23
14.15%
25.10.22
25.10.22
Probably not worthwhile Investment
Avenue Therapeutics Inc.
Start price
Target price
Perf. (%)
€14.42
03.10.22
03.10.22
-
03.10.23
03.10.23
-81.66%
07.10.22
07.10.22
Risky Investment
Motus GI Holdings Inc.
Start price
Target price
Perf. (%)
€2.26
03.10.22
03.10.22
€3.00
03.10.23
03.10.23
22.12%
06.10.22
06.10.22
Could be worthwhile Investment >10% per year
Capable Management
Very good company culture
Little innovation